The synthetic lethal interaction between PARP inhibition and BRCA1/2 mutations formed the basis for the approval of PARP inhibitors, such as Olaparib and Talazoparib, as monotherapies for patients with loss-of-function germline BRCA-mutated HER2-negative breast cancer (16). The gene discussed is BRCA1; the disease is breast cancer.